GLP-1 Drugs: First-In-Class Longevity Therapeutics

2025 evidence positions GLP-1 drugs as the first pharmaceutical class with comprehensive longevity benefits—12-15% all-cause mortality reduction.

5 min read

Related Modules

Continue your learning journey with these related topics

NAD+ declines 50% by age 50. Restoring it with NMN or NR reverses aging markers, enhances mitochondrial function, and extends lifespan.

Synthesize all 9 longevity breakthroughs into a personalized, evidence-based protocol that maximizes healthspan and lifespan.

Senolytic foods, autophagy enhancers, and polyphenols that target the 11 pathways of cellular aging.